Quick Search 
Drugs of the Future
Register or sign in

Drugs Fut 2018, 43(12): 873
ISSN 0377-8282
e-ISSN 2013-0368
Copyright 2018 Clarivate
CCC: 0377-8282
DOI: 10.1358/dof.2018.043.12.2898664
Tagraxofusp. Recombinant human fusion protein of diphtheria toxin and IL-3, Treatment of blastic plasmacytoid dendritic cell neoplasm
O'Brien, J., Rizzieri, T., Rizzieri, D.A.
Tagraxofusp is a novel therapeutic agent in clinical trials for acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). As a fusion protein of diphtheria toxin and interleukin-3 (IL-3), it targets cells expressing the IL-3 receptor (IL-3R) and leads to cell death. AML, MDS and BPDCN all have leukemic cells and cancer stem cells expressing high levels of IL-3R making tagraxofusp an ideal therapeutic approach to target tumor cells. Preclinical and clinical studies have demonstrated minimal toxicity, selectivity of the drug for tumor cells and promising clinical benefit from this agent. In this review, we will highlight the preclinical pharmacology and efficacy and discuss the results of clinical trials examining tagraxofusp treatment to date

Full Text: PDF 

© Clarivate. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie PolicyManage cookie preferences